Hayder et al [1] described a well-conducted clinical trial comparing topical erythromycin-Zinc acetate complex lotion against topical erythromycin get in treating patients with acne vulgaris of mild to moderate severity. This study bears several limitations, such as its being singleblinded, a predetermined recruitment period not clearly delineated, the response rate and completion rate unclear, and the randomisation process, if any, not being explicit. However, the authors courageously admitted some of these limitations. We agree that their analyses and conclusions are largely valid, statistically significant, and clinically pertinent.
